Please ensure Javascript is enabled for purposes of website accessibility

Here's What Pushed Aurinia Pharmaceuticals Inc. Up 16.8% in September

By Cory Renauer - Oct 3, 2018 at 5:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Steady progress for the company's experimental lupus treatment took an important step forward

What happened

Shares of Aurinia Pharmaceuticals Inc. (AUPH -1.61%), a biotechnology company developing an experimental new lupus therapy, rose 16.8% in September, according to data from S&P Global Market Intelligence. Analyst attention following an important step forward for the company's lead candidate pushed the stock higher.

So what 

Aurinia's lead candidate, voclosporin, is in a pivotal study that could make it the first therapy specifically approved for the treatment of lupus nephritis. Late in September, the company finished enrolling patients into the Aurora study -- which means 52-week kidney response data should be ready in 2019.

Person drawing an upward sloping chart with their fingers.

Image source: Getty Images.

Estimates vary, but perhaps a million Americans have systemic lupus erythematosus, and around two-fifths eventually progress to kidney-threatening lupus nephritis. With this in mind, a Cantor Fitzgerald analyst recently issued a price target that suggested Aurinia stock has more than 200% upside.

Now what

Voclosporin's chance for success in its ongoing pivotal study looks better than average, considering its performance in midstage testing. Last year, Aurinia showed us that adding its candidate to standard care led to significantly greater remission rates at 48 weeks. Providing a significant benefit in the larger setting could make voclosporin a blockbuster drug.

Aurinia also initiated a dry eye trial with voclosporin earlier this year that will put it up against Allergan's former blockbuster Restasis. If successful, there could be further gains before the end of the year.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aurinia Pharmaceuticals Inc. Stock Quote
Aurinia Pharmaceuticals Inc.
$10.99 (-1.61%) $0.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.